



PRESS RELEASE |

IBA Molecular Selects CoreLinQ to Offer a ¹⁸F-NaF Software Program

SureStart™ Peer Review and Orientation System Supports PET Imaging Sites

Dulles, VA, June 5, 2015 -IBA Molecular North America, Inc. (IBA) announced today that it has selected CoreLinQ Innovations (CoreLinQ) to market SureStart™, an innovative web-based Peer Review and Orientation system designed to support ¹⁸F-NaF Sodium Fluoride PET Bone Imaging sites. This on-demand HIPAA-compliant service provided by CoreLinQ will be offered to IBA Molecular's nationwide network of customer sites.

SureStart will provide two complementary services to PET imaging sites launching or re-activating their ¹⁸F-NaF PET Bone Imaging programs. First, on-demand Peer Review will provide timely feedback on images and reports, with comparative observations on scan protocol, images, interpretation and report elements by physicians with extensive experience in NaF PET/CT interpretation. The goal is to support PET interpreters in delivering quality and confident diagnostic reports to the referring community.

Second, PET sites can access educational resources available through PETLinQ IQ, IBA's PET web portal. Tutorial slide decks, guides, literature references and case studies are available, addressing the key aspects of Sodium Fluoride bone imaging, including patient preparation, scan protocols, interpretative considerations, limitations and pitfalls. These resources are authored and created by Dr. Robert Bridwell, noted PET physician and educator.

"Studies have shown that ¹⁸F-NaF Sodium Fluoride PET can have a significant impact on oncologic case management," noted Lee Karras, President of IBA. "SureStart will help ensure quality diagnostic images and reports that can positively influence patient care."

"We are pleased that IBA recognized CORELinQ's proven track record in peer review technologies and software platforms within the PET and general radiology space. These solutions provide IBA with powerful tools to effectively market SureStart to its customer base," said Harsha Hatti, President and CEO of CoreLinQ Innovations. "We are committed to providing imaging sites with a suite of intuitive and robust products to enhance their value to the referring community."

SureStart, which will be available for a limited time, is a flexible service which can be matched to the particular needs of the PET imaging site. The web-based system can be set up within one day, requires no onsite server, and can be applied to a range of PET study types.

About IBA Molecular

IBA Molecular is a leading developer, manufacturer and distributor of radiopharmaceutical products and supporting services used in molecular imaging with operations throughout Europe, Asia and the U.S. IBA Molecular has a unique product portfolio and pipeline of diagnostic and therapeutic tracers aimed at

advancing the development of the global movement towards personalized medicine and making molecular imaging/therapy a major discipline in healthcare. The company also provides educational, technical and marketing support to medical specialists worldwide to help better respond to patient needs. IBA Molecular is jointly owned by SK Capital Partners and Ion Beam Applications S.A. IBA Molecular North America, Inc. is the US operating entity of IBA Molecular.

For more information, please visit www.ibamolecular.com

About CoreLinQ

CORELinQ Innovations is a healthcare technology company led by a seasoned group of individuals, averaging nearly 20 years of industry work experience in radiology technology, healthcare operations, compliance, client relations, account management, research/development and finance. The company has four key divisions, CORELinQ-Innovations, CORELinQ-Labs, CORELinQ-Pharma, and CORELinQ-Ventures. The firm offers a suite of industry-leading products and services, including image distribution/viewing, report management and distribution, fully integrated RIS/billing and RCM services to improve workflow and reduce costs without compromising patient care.

For more information, please visit www.corelinq.com

Contact:

IBA Molecular North America, Inc.

Peter Burke
Vice President, Sales & Marketing
IBA Molecular North America, Inc.
peter.burke@ibamolecular.com

CoreLinQ Innovations

Media Relations:
1-888-247-7563, ext. 2
Media.relations@corelinq.com